Tonia Nesheiwat

Caribou Biosciences (United States) — United States

Medicine · Health Sciences

15h-index746citations52works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(33), CAR-T cell therapy research(29), Protein Degradation and Inhibitors(14), Biosimilars and Bioanalytical Methods(12), Cancer Treatment and Pharmacology(7)

Publications52 total

A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)
The Journal of Rheumatology·2025Open Access
BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma
Journal for ImmunoTherapy of Cancer·2023· 19 citedOpen Access
Adjusted comparison of outcomes between patients from CARTITUDE-1 <i>versus</i> multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
Haematologica·2022· 19 citedOpen Access
A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
Blood·2022· 17 cited
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)
Clinical Lymphoma Myeloma & Leukemia·2022· 6 cited
MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy
Clinical Lymphoma Myeloma & Leukemia·2022· 1 citedOpen Access
Poster: MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)
Clinical Lymphoma Myeloma & Leukemia·2022
Poster: MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy
Clinical Lymphoma Myeloma & Leukemia·2022
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood·2022· 182 citedOpen Access
OAB-044: Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting antibody-drug conjugate treatment
Clinical Lymphoma Myeloma & Leukemia·2022
OAB-062: Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment
Clinical Lymphoma Myeloma & Leukemia·2022
OAB-043: Ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma and early relapse after initial therapy: biological correlative analyses and updated clinical results from CARTITUDE-2 Cohort B
Clinical Lymphoma Myeloma & Leukemia·2022
P-239: Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life standard of care (SOC) treatments: results from the LocoMMotion study
Clinical Lymphoma Myeloma & Leukemia·2022
P-243: Subgroup analyses from the LocoMMotion study of real-life current standard of care (SOC) in patients with relapsed/refractory multiple myeloma (RRMM)
Clinical Lymphoma Myeloma & Leukemia·2022
OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
P-259: Ciltacabtagene autoleucel (cilta-cel) versus real world clinical practice in triple-class exposed multiple myeloma: adjusted comparison of patient reported outcomes from CARTITUDE-1 and LocoMMotion
Clinical Lymphoma Myeloma & Leukemia·2022
P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2022· 1 cited
Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma
Current Medical Research and Opinion·2022· 7 cited
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.
Journal of Clinical Oncology·2022· 3 cited
P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
HemaSphere·2022· 2 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Jordan M. Schecter(38), Katja Weisel(29), Hermann Einsele(22), Lida Pacaud(21), María‐Victoria Mateos(20), Helen Varsos(20), Tito Roccia(20), Martin Vogel(18), Hartmut Goldschmidt(17), Yaël C. Cohen(17), Michel Delforge(16), Philippe Moreau(15), Christina Corsale(15), Niels W.C.J. van de Donk(14), Vadim Strulev(14), Adam D. Cohen(14), Kevin C. De Braganca(14), Mounzer Agha(14), Enrique Zudaire(13), Valerio De Stefano(12)